What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="This article explores some of the latest developments in antibody-based molecular discovery, engineering, and optimisation."> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="This article explores some of the latest developments in antibody-based molecular discovery, engineering, and optimisation."> <meta property="og:title" content="What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?"> <meta name="twitter:description" content="This article explores some of the latest developments in antibody-based molecular discovery, engineering, and optimisation."> <meta name="twitter:title" content="What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/nextgen-biomed/resources/whats-next-for-antibody-based-therapeutic-discovery-and-optimisation"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Antibody-Discovery--scaled.jpg"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Antibody-Discovery--scaled.jpg"> <meta property="og:url" content="https://oxfordglobal.com/nextgen-biomed/resources/whats-next-for-antibody-based-therapeutic-discovery-and-optimisation"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="nextgen-biomed"> <div class="body-wrapper hs-content-id-177607186815 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/nextgen-biomed" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/nextgen-biomed/events/nextgen-biomed-2025" class="pill center"> <div class="b">NextGen Biomed 2025</div> <div class="heading-smallcaps"> 12 - 14 Mar 2025 | London, UK </div> </a> <a href="/nextgen-biomed/events/cell-2025" class="pill center"> <div class="b">Cell 2025</div> <div class="heading-smallcaps"> 11-12 Nov 2025 | London, UK </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/nextgen-biomed/online#Process%20Challenges%20in%20ATMP%20Development:%20Overcoming%20Hurdles%20for%20Successful%20Manufacturing" class="cta" target="_blank"> <h3 class="other-resources">01/11/24 - Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>NextGen Biomed is the platform to advance the fields of biologics, vaccines & novel therapeutics approaches, helping to deliver life-saving medicines to patients faster.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>NextGen Biomed is committed to supporting R&D scientists, as well as drug development and manufacturing experts, working with biologics, peptides, and oligonucleotides to overcome complexities at every stage of the drug product lifecycle.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>The latest in from nextgen biomed research & development</p> </div> <div class="subnav-item-content-more"> <a href="/nextgen-biomed/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All NextGen Biomed Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/University%20College%20London%20Hospitals%20Begins%20Clinical%20Trial%20for%20One-Off%20CAR%20T%20Treatment%20for%20Lupus%201.jpg" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/nextgen-biomed/resources/university-college-london-hospitals-begins-clinical-trial-for-one-off-car-t-treatment-for-lupus">University College London Hospitals Begins Clinical Trial for One-Off CAR T Treatment for Lupus</a> </h3> <div class="resource-abstract"> <span class="resource-date">08/11/24 - </span> The possibility of a one-off treatment for lupus could offer hope to 69,000 patients in the UK. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/clesrovimab-shows-positive-results-as-preventative-treatment-for-rsv-in-pre-term-and-full-term-infants">07/11/24 - Clesrovimab Shows Positive Results as Preventative Treatment for RSV in Pre-Term and Full-Term Infants</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/nextgen-biomed/resources/the-nist-awards-1-5-million-to-improve-standardisation-in-regenerative-medicine">31/10/24 - The NIST Awards $1.5 Million to Improve Standardisation in Regenerative Medicine</a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/nextgen-biomed/resources/sponsored/webinar/wuxibiologics/sp-webinar-optimizing-bispecific-antibody-production-from-identifying-optimal-pairings-to-scale-up-processes"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Digital%20Marketing/Webinars/Email%20and%20Social%20Collateral/NGB%20-%20Wuxi%20Biologics/WuXi%20Biologics.png" class="sponsor-resource-cover-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes </h3> <div class="resource-abstract"> On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Antibody & Protein Engineering | Industry Spotlights & Insight Articles </div> <h1 class="heading"> What’s Next for Antibody-Based Therapeutic Discovery and Optimisation? </h1> <div class="byline"> Edited by Tia Byer | 25 April 2022 </div> <div class="abstract"> As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation. </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Antibody-Discovery--scaled.jpg" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap">  <p>Antibody-drug products are a dominant biopharmaceutical with steady market demand. The global worth of antibodies in 2022 was valued at 145.7 billion USD and is projected to surpass 248.9 billion USD by the end of 2027, at a CAGR of 11.31%. Prominent industry players are Novartis, Pfizer, Eli Lilly, A.G. Scientific, Bristol-Myers Squibb, AbbVie, and F. Hoffman-La Roche.</p>   <p>Key market drivers include the growing interest in alternative therapeutics such as monoclonal and polyclonal antibodies and the widespread outbreak of infectious diseases requiring protein treatments. In particular, the 2020 outbreak of COVID-19 intensified investigation into the genetic dynamics of transmissible mutation and modification.</p>   <p>The increasing prevalence of chronic illnesses such as cancer, diabetes, and autoimmune diseases likewise drives antibody therapeutic sales, encouraging continuous and essential research and development. Investments in antibody manufacturing have sparked significant interest in the burgeoning field.</p>   <blockquote class="wp-block-quote is-style-large"><p>Current antibody targets often come with complex mechanisms that can be difficult to suppress or augment, requiring a bespoke approach to discovery.</p></blockquote>   <p>This article explores some of the latest developments in antibody-based molecular discovery, engineering, and optimisation. We profile one of the most exciting case studies divulged by the CRUK-AstraZeneca Antibody Alliance Laboratory* at our most recent<a href="https://oxfordglobal.com/biologics-series/" target="_blank" rel="noreferrer noopener"> Biologics UK: In-Person</a> event on 21<sup>st</sup> and 22<sup>nd</sup> March 2022.</p>   <h2 id="h-overcoming-challenges-in-novel-antibody-discovery">Overcoming Challenges in Novel Antibody Discovery:</h2>   <p>Despite its market dominance, growth deterrents to antibody therapeutic discovery prevail. Antibody discovery technologies are well established, with an abundance of sophisticated display platforms and cutting-edge antibody libraries available across the industry. However, as Denice Chan, Senior Scientist at the Cancer Research UK - AstraZeneca Antibody Alliance Laboratory, puts it, “with such extensive choice, we must accurately mix and match these methodologies.” Therefore, appropriate application selection is vital.</p>   <p>A larger difficulty lies in the increasingly large and diverse range of target classes within the field. Current antibody targets often come with complex mechanisms that can be difficult to suppress or augment, requiring a bespoke approach to discovery. What works for one target might not work for another. This means that the antibody discovery strategy must be tailored to each project’s requirements. Personalised discovery approaches can be labour-intensive, time-consuming, and expensive.</p>   <ul><li><a href="https://oxfordglobal.com/biologics/resources/targeting-complex-membrane-proteins-an-understudied-opportunity/" target="_blank" rel="noreferrer noopener">Could Targetting Complex Membrane Proteins be an Understudied Opportunity in Antibody Engineering?</a></li><li><a href="https://oxfordglobal.com/biologics/resources/bispecific-antibody-drug-conjugates/" target="_blank" rel="noreferrer noopener">Discover More About Optimising Receptor Trafficking with Bispecific Antibody-Drug Conjugates</a></li><li><a href="https://oxfordglobal.com/biologics/resources/t-cell-engagement-and-redirection-strategies-methods-and-t-cell-design/" target="_blank" rel="noreferrer noopener">Advancing Antibody Binding with T Cell Engagement and Redirection</a></li></ul>   <p></p>   <p>Finally, there is the challenge of discovering new targets. “As we know, the lower hanging fruits of the industry are rapidly being picked,” Chan explained. Looking ahead, appropriate target validation and disease positioning must become a priority. Phenotypic and genomic approaches provide ample opportunity for target discovery, but as Chan puts it: “most importantly, we need to be driven from a disease biology mindset right from the start of a project.”</p>   <p>It is important to apply such techniques at the start of a project because it both strengthens the positioning of the therapeutic candidate and provides information on how best to shape the discovery campaign and programmes. Early target validation and disease positioning add significant value to later antibody development. </p>   <h2>Industry Case-Study:</h2>   <p>So how is the industry addressing the continued need for next-generation antibody discovery and development? The CRUK-AstraZeneca Antibody Alliance Laboratory are making impactful strives in the tailored discovery of antibodies for a diverse range of targets.</p>   <h2>Tailoring Discovery – CRUK-AstraZeneca Antibody Alliance Laboratory:</h2>   <p>The Cancer Research UK-AstraZeneca Antibody Alliance Laboratory (AAL) collaborate with academic researchers on novel antibody discovery projects to accelerate the delivery of therapies and diagnostics for cancer patients. As a unique alliance, the AAL has access to world-class antibody technologies and targets.</p>   <p>The combined expertise of the AAL concentrates on the discovery and optimisation of novel cancer medicines, antibody diagnostics, and tool antibody reagents. With a diverse portfolio of 9 projects spanning across therapeutic, diagnostic, and target validation areas, the initiative likewise possesses a diverse set of target classes.</p>   <p>One such target is the Arginase 2 project (ARG2), which is a collaboration between the Cerundolo group at the University of Oxford and the AAL. ARG2 is a homotrimeric enzyme that catalyses the conversion of arginine to ornithine and urea. So far, the collaboration has demonstrated an immunosuppressive role for ARG2 in acute myeloid leukaemia (AML). According to Chan, “this presents a therapeutic opportunity for ARG2 suppressing antibodies to restore anti-tumoral immunity to AML patients.”</p>   <blockquote class="wp-block-quote is-style-large"><p>"Adapting to the needs of the targets is the key to the successful generation of these antibody therapeutics"</p></blockquote>   <p>The AAL adopts a bespoke approach for the discovery of novel antibodies for the diverse range of targets in their portfolio. To mitigate the challenges that came with the difficult enzyme target ARG2, the lab employed early functional screening in masses and a highly comprehensive affinity maturation strategy. “If there is one thing that we learnt from this project, it is that we need to listen to the targets, because adapting to the needs of the targets is the key to the successful generation of these antibody therapeutics,” she continued.</p>   <h2>Impactful Change:</h2>   <p>As the antibody industry reaches new heights, both in terms of next-generation development and market dominance, we can expect to see continued growth and product output. The oncology industry, in particular, is expected to benefit from the latest discoveries and pipelines in antibody-based therapies. The market for autoimmune disease treatment is likewise forecast to reap the rewards of sustained demand for the antibody field. At <a href="https://oxfordglobal.com/" target="_blank" rel="noreferrer noopener">Oxford Global</a> we look forward to seeing such results.</p>   <p>*<sub>renamed the Cancer Research Horizons-AstraZeneca Antibody Alliance Laboratory</sub></p>   <p><em>Want to find out more about the latest market news and industry insights? Join our <a href="https://oxfordglobal.com/virtual-symposium-oligonucleotides/" target="_blank" rel="noreferrer noopener">Oligonucleotide Chemistry & Therapeutics Symposium</a> and discover the latest in oligonucleotides chemistry, process and analytical development, therapeutics, and antisense therapy. </em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Biologics/Antibodies%20Case%20Study%20Report%20Websize.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development"> <h4> Accelerating Biologics Discovery & Development Through Transformative Technologies & Overcoming Strategic Challenges </h4> <div class="abstract"> A concise report featuring insights from the prominent thought leaders of Biologics 2024 </div> <div class="read-more"> <a href="/nextgen-biomed/resources/case-studies/accelerating-biologics-discovery-and-development" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/NextGen%20Biomed/Archon%20Biosciences%20Announces%20$20m%20of%20Seed%20Funding%20for%20its%20Nobel-Winning%2c%20AI-Driven%20Antibody%20Cage%20Technology.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology"> <h4> Archon Biosciences Announces $20m of Seed Funding for its Nobel-Winning, AI-Driven Antibody Cage Technology </h4> <div class="abstract"> This investment signals the UW spin out’s ‘emergence from stealth’, showcasing their unique antibody platform. </div> <div class="read-more"> <a href="/nextgen-biomed/resources/archon-biosciences-announces-20m-of-seed-funding-for-its-nobel-winning-ai-driven-antibody-cage-technology" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Documents/Whitepaper%20Upload%20TC%2025.10.24/Conjugate-clean-up-and-characterize-ADCs-on-Unagi-and-Stunner_RevA.jpg" class="cover-graphic-image"> </div> </a><div class="content"><a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner"> <h4> Conjugate, clean-up, & characterize ADCs on Unagi & Stunner </h4> <div class="abstract"> </div> <div class="read-more"> <a href="/nextgen-biomed/resources/conjugate-clean-up-characterize-adcs-on-unagi-stunner" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things NextGen Biomed </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177053686099">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/nextgen-biomed\/resources\/whats-next-for-antibody-based-therapeutic-discovery-and-optimisation"]); _hsq.push(["setPageId", "hubdb-177607186815-30817717-181072999231"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177607186815-30817717-181072999231", "legacyPageId": "hubdb-177607186815-30817717-181072999231", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177607186815, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "53731462-8532-4d84-89f1-badfaf5bdf57", ticks: 1732377871422, page_id: 177607186815, dynamic_page_id: "hubdb-177607186815-30817717-181072999231", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177607186815-30817717-181072999231", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

What’s Next for Antibody-Based Therapeutic Discovery and Optimisation?